[go: up one dir, main page]

EP1461409A2 - Subtilisin varianten mit verbesserten eigenschaften - Google Patents

Subtilisin varianten mit verbesserten eigenschaften

Info

Publication number
EP1461409A2
EP1461409A2 EP02793057A EP02793057A EP1461409A2 EP 1461409 A2 EP1461409 A2 EP 1461409A2 EP 02793057 A EP02793057 A EP 02793057A EP 02793057 A EP02793057 A EP 02793057A EP 1461409 A2 EP1461409 A2 EP 1461409A2
Authority
EP
European Patent Office
Prior art keywords
subtilisin
modified
mutations
mutation
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02793057A
Other languages
English (en)
French (fr)
Inventor
Ulrich c/o Direvo Biotech AG Kettling
Andre c/o Direvo Biotech AG Koltermann
Oliver c/o Direvo Biotech AG Kensch
Rene c/o Direvo Biotech AG Kuhlemann
Ulrich c/o Direvo Biotech AG Haupts
Markus c/o Direvo Biotech AG Rarbach
Konrad c/o Direvo Biotech AG Odendahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Direvo Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Direvo Biotech AG filed Critical Direvo Biotech AG
Priority to EP02793057A priority Critical patent/EP1461409A2/de
Publication of EP1461409A2 publication Critical patent/EP1461409A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase

Definitions

  • the present invention provides subtilisin variants with improved characteristics, including improved substrate affinity, catalytic activity, catalytic efficiency and stability under washing conditions as well as overall wash performance.
  • the subtilisin variants are therefore useful additives in cleaning compositions.
  • Proteases are enzymes that catalyze the hydrolysis of peptide bonds in a protein's backbone. Protease with low substrate specificity are required in order to degrade various protein soils to smaller fragments and, thereby, to support a detergent's " action of removing stains like egg, grass, grain etc. from textiles and other materials. Subtilisins are used for this purpose for more than 30 years with large success, mainly as additives in cleaning compositions, e.g. laundry detergents. Consequently, detergent proteases account today for approximately 30% of total worldwide enzyme production. A large number of different subtilisins and subtilisin- like enzymes have been isolated and cloned from several microorganisms including mainly bacillus species (e.g.
  • subtilisins Bacillus subtilis, Bacillus lentus, Bacillus licheniformis, Bacillus amyloliquefaciens) , but also from other organisms (e.g. Tritirachium album, Thermoactinomyces vulgaris).
  • subtilisins need to be stable and active under the harsh conditions of the automatic washing procedure (medium to high temperature, alkaline pH, oxidizing conditions, surfactants, etc.). Consequently, a large number of studies have been done on the design of subtilisins to fulfill these requirements.
  • subtilisin derivatives which are modified by substitution of methionine, trypthophane, lysine or cysteine with alanine or serine resulting in improved stability under highly oxidizing conditions.
  • subtilisin variants Analogously, a number of subtilisin variants have been obtained that are better suited for technical conditions such as highly alkaline pH, high temperature, high concentrations of detergents, etc.
  • thermally stable serine proteases are created by introducing cysteine at position 206.
  • Subtilisins with enhanced thermal stability were obtained by modifications at the calcium-binding sites at positions 131 and 172 (see US Patent No. 5,260,207).
  • Subtilisin variants showing alterations in characte ⁇ stics as thermal and alkaline stability were described in US Patent No. 5,972,682. Besides of stability, the utility of an enzyme is further characterized by its catalytical behavior in its proposed technical field.
  • Multi-mutations also can result in increased proteolytic activity as disclosed in EP-A- 0451244 describing substitutions at position 123 and 274.
  • US Patent No. 6,287,841 discloses subtilisin mutants derived from PB92 subtilisin or Subtilisin 309 by substitutions at combinations of positions 60, 87, 97, 99, 102, 116, 117, 126, 127, 128, 130, 133, 134, 154, 158, 159, 160, 164, 169, 175, 180, 182, 193, 197, 198, 203, 211 and 216 corresponding to these precursor subtilisins, having improved wash performance or/and improved stability.
  • subtilisins described in WO 91/00345 and EP-A-0405901 with change of the net electrostatic charge in favour to an isoelectric point lower or higher than that of the parent subtilisins, resulting in subtilisins with improved adsorption to the substrate, i.e. protein soils on textile surfaces or other material to be cleaned, encompass among other mutations a modification done at position 54 with the glutamic acid being substituted by Thr, Tyr or Gly.
  • WO 92/11348, as well as US Patents Nos. 5,631,217 and 5,482,849 disclose the substitution at position 54 by aspartic acid.
  • US Patent 5,316,935 discloses modifications selected from D60N, D97G, Q103R, G131D, S182G, S188P, D248A, D248L, D248N or T255, and optionally E156G and/or N218S when the subtilisin already contains the substitution N181S resulting in modified subtilisins as catalysts with improved stability and/or catalytic activity in organic solvents.
  • US 4,760,025 describes subtilisin variants derived from subtilisin naturally produced by Bacillus amyloliquefaciens that are substituted at positions 32, 155, 104, 222, 166, 64, 33, 169, 189, 217, 157 by any different amino acid.
  • US 5,700,676 also pertains to improved subtilisin modified at selected positions by substitution of the amino acid with a different naturally occurring amino acid.
  • mutant subtilisins distinguished from the parent subtilisins by different amino acids at one or more selected positions with the different amino acid being more positive or negative than the amino acid in the corresponding position in the parent subtilisin resulting in enzyme mutants exhibiting improved wash performance.
  • WO 95/07991 describes subtilisin mutants with improved properties as decreased adsorption to and increased hydrolysis of an insoluble substrate, wherein the modifications are defined substitutions in the range of positions 199 to 200, either at least at one position or at two positions. For example, in case of a double substitution there are a number of amino acids proposed substituting the tyrosine at position 217 with the preferred amino acid being leucine.
  • EP-A-0380362 which pertains to the use of subtilisin mutants in chemical reaction in a non-native environment, discloses lysine or leucine as appropriate substituating amino acids at position 217, whereas WO 96/09396 describes a calcium-free thermostable subtilisin mutant comprising the modification Y217K, inter alia.
  • WO 01/07578 describes subtilisin-like protease variants having decreased immunogenicity evolved by the combination of defined substitutions at one or more positions in one or more epitope regions (ranging from 108 to 126 AA; 221-246 AA), at two or more positions in one or more epitope region (113-125 AA; 221-246 AA), at one or more positions in two or more of the epitope regions (108-125 AA; 221-246 AA; 70-84 AA) or at two or more positions in one or more of the epitope regions (ranging from 103-126 AA, 220-246AA, 70-84 AA).
  • WO 95/30010 concerns variants with decreased adsorption to and increased hydrolysis of an insoluble substrate and discloses defined amino acid substitutions in six loop regions of BPN' subtilisin, with the first loop region ranging from AAs 59 to 66, the second loop from AAs 95 to 107, the third loop from AAs 126 to 133, the fourth loop from AAs 154 to 167, the fifth loop from AAs 187 to 191, and the sixth loop from AAs 199 to 220 with the BPN' variants having modified amino acid sequences comprising one or more substitutions in one or more of the loop regions (first to fifth) or modifications as described within the sixth loop region in combination with substitution(s) in one of the aforementioned loop regions.
  • WO 95/10615 describes subtilisin variants with altered properties compared to those of the precursor subtilisins having a substitution at position 76 and further substitutions at selected positions (99, 101, 103, 104, 107, 123, 27, 105, 109, 126, 128, 135, 156, 166, 195, 197, 204, 206, 210, 217, 218, 222, 260, 265, 274) with the main substitution being N76D.
  • WO 99/20770 pertains to subtilisin variants with a substitution at position 103 in combination with one or more substitutions at amino acid residues in the range from 1 to 275, with the main substitution being defined as S103A.
  • the variants according to US Patent 6,312,936 comprise substitutions at position 103 and 236 and/or 245 and further substitutions within the range from AAs 1 to 275 with the main substitutions being S103A, Q236H, Q246L.
  • the concentration of protease needed for a sufficient removal of protein stains from textiles is between 1 and 5 mg per liter washing liquid. This leads to a worldwide annual consumption of more than 500.000 kg enzyme per year. Furthermore, the high protease concentration corresponds to an increased chance of exposure to the potentially immunogenic protein and, thereby, to an increased probability of allerge ⁇ ic effects.
  • subtilisin variants with improved characteristics, especially subtilisin variants that can be applied technically as additives in cleaning compositions at significantly lower concentrations as compared to known subtilisin variants.
  • Further improved characteristics may include, but are not limited to, higher catalytic rates under application conditions, higher substrate affinity under application conditions, faster removal of protein stains from the particular surface under application conditions, improved stain removing ability at low laundering temperature, better wash performance, improved stability upon storage, improved stability during use, and improved resistance to self-degradation under application conditions.
  • the present invention provides subtilisin variants that are improved for at least one of these characteristics. These subtilisins are useful additives in cleaning compositions such as laundry detergents and other technical or industrial applications.
  • the present invention provides
  • a subtilisin variant having improved characteristics under technical conditions such as a laundry detergent solution, in particular a modified subtilisin having at least one mutation in an amino acid sequence of a precursor subtilisin at a position numbered according to the amino acid sequence of the mature subtilisin BPN' shown in SEQ ID NO: l, wherein said at least one mutation is selected from (a) E54D or E54G, (b) Q103R or Q103K, (c) T133K, (d) E156K or E156A, and (e) Y217H, or mutations at the respective positions which are homologous to said mutations (a) to (e), provided that in case of mutations E54D, Q103R, E156K or E156A the modified subtilisin has at least one more of said mutations (a) to (e);
  • (6) a microorganism which comprises the DNA as defined in (4) above and/or the vector as defined in (5) above;
  • Figure 1 shows a plasmid map of the shuttle vector pBVP43-Sub.
  • Figure 2 shows an alignment of several subtilisins of the genus Bacillus, wherein
  • Sub DY is subtilisin DY (Bacillus subtilis; SEQ ID NO: 3), Sub BLI is subtilisin
  • subtilisin E Bacillus subtilis
  • subtilisin BPN' Bacillus amyloliquefaciens
  • Sub Sav is subtilisin Savinase (Bacillus lentus; SEQ ID NO:5).
  • Figure 3 shows “exemplarily” the improvement of subtilisin variants relativ to the subtilisin E wild type over 4 rounds of directed evolution towards higher activity in laundry detergents.
  • FIG 4 shows the protein degradation performance of subtilisin variant 22 in comparison to wild type subtilisins. All enzymes were applied at concentrations of 2.5 mg/l.
  • Figure 5 Determination of the amount of enzyme of variant 50, 1, 4 or 22 compared to the subtilisin E wild type needed in order to achieve a certain protein degradation.
  • Figure 6 shows a Michaelis Menten plot of subtilisin variants 1, 4, 22. All enzymes were applied at concentrations of 2.5 mg/l.
  • Figure 7 shows a comparison of the protein degradation and solubilization performance between a laundry detergent containing variant 22 and a laundry detergent containing a commercially available subtilisin.
  • the present invention provides subtilisin variants with improved characteristics compared to those of the respective precursor subtilisin enzymes. These improved properties enable a better utility in cleaning compositions.
  • subtilisins are serine proteases with low substrate specificity and structural homology to subtilisin E from Bacillus subtilis (Biochim. Biophys. Acta 1543 (2000) 203-222). Serine proteases are characterized by the catalytic triade comprising aspartate-histidine-serine, reading from the amino to the carboxy terminus.
  • subtilisins derive from bacterial strains, such as subtilisin E (Bacillus subtilis), subtilisin 309 (Bacillus lentus), subtilisin BPN' (Bacillus amyloliquefaciens) or subtilisin Carlsberg (Bacillus licheniformis).
  • subtilisins Derived from different species the amino sequences of naturally occuring subtilisins are not entirely homologous, but differ in amino acid substitutions, insertions and deletions. For the purpose of this invention all positions mentioned in the context of subtilisin are equivalent to the numbering of the mature form of the naturally occuring subtilisin BPN' of Bacillus amyloliquefaciens.
  • amino acids mentioned are abbreviated according to the following list either in one- or in three-letter code.
  • a “variant” in accordance with the invention has an amino acid sequence not found in nature, but is instead derived from the amino acid sequence of a "precursor” enzyme by one or more amino acid substitutions (in the present invention also referred to as "mutation").
  • subtilisins can be naturally occuring subtilisins such as subtilisin E (Bacillus subtilis strain 168; SEQ ID NO: 2), subtilisin BPN' (Bacillus amyloliquefaciens; SEQ ID NO: l), subtilisin DY (Bacillus subtilis strain DY; SEQ ID NO:3), subtilisin Carlsberg (Bacillus licheniformis; SEQ ID NO:4), subtilisin savinase (Bacillus lentus; SEQ ID NO: 5), subtilisin J (Bacillus stearothermophilus; SEQ ID NO: 6), alkaline elastase YaB (Bacillus sip.
  • subtilisin E Bacillus subtilis strain 168; SEQ ID NO: 2
  • subtilisin BPN' Bacillus amyloliquefaciens
  • subtilisin DY Bacillus subtilis strain DY
  • subtilisin Carlsberg Bacillus licheniformis
  • subtilisin E subtilisin E
  • subtilisin E subtilisin E
  • subtilisins recombinant or engineered subtilisin
  • recombinant subtilisins can serve as precursor subtilisins.
  • the characteristics of the subtilisin include one, several, or all of the following parameters "Km", “catalytic activity”, “catalytic efficiency” and “wash performance”.
  • Km or "Michaelis Menten constant"
  • catalytic activity are kinetic parameters of an enzyme according to the definitions of Michaelis and Menten (see Fersht, A., Enzyme Structure and Mechanism, W. H. Freeman and Company, New York, 1995).
  • Km describes the affinity of the enzymes to its substrate.
  • the "catalytic activity” used herein describes the rate of conversion of the substrate under defined conditions.
  • kinetic data are obtained by measuring the hydrolysis of substrates over time.
  • Substrates were fluorescent labeled casein or bovine serum albumin molecules. The degradation was measured over time using confocal fluorescence spectroscopy (see WO9416313).
  • wash performance used in this invention describes the solubilization and degradation of proteins bound to textiles by the investigated protease applied in a detergent without proteases and compared to the effect of this detergent alone.
  • original amino acid means the amino acid found in the subtilisin E wild type enzyme at the particular position. It should be noted, that if another subtilisin is to be improved by introducing the amino acid substitutions disclosed in the present invention, the wild type amino acid residue at the particular position might differ from the "original amino acid”. Substitutions are usually described as follows: original amino acid; position; substituted amino acid.
  • subtilisin variants generated by means of directed evolution as described in the Experimental Section have surprisingly been found to have improved characteristics as industrial enzymes such as detergent proteases.
  • the subtilisin variants according to embodiment (1) of the present invention comprise one or a combination of the particular mutations (a) to (e), or mutations at the the respective positions which are homologous to said mutations (a) to (e).
  • the mutation
  • E54D or E54G means that at position 54, glutamic acid is exchanged by an aspartic acid or a glycine
  • Q103R or Q103K means that at position 103, glutamine is exchanged by an arginine or a lysine;
  • T133K means that at position 133, threonine is exchanged by a lysine
  • E156K or E156A means that at position 156, glutamic acid is exchanged by a lysine or an alanine;
  • Y217H means that at position 217, tyrosine is exchanged by a histidine.
  • "Homologous mutations" according to the present invention are mutations which a person skilled in the art would consider homologous, i.e. equivalent. Thus if the mutated (the newly introduced) amino acid is e.g. a lipophilic amino acid, such as Leu, then other lipophilic amino acids such as He are also applicable .
  • subtilisin comprises at least two of - the mutations (a) to (e) which includes the following substitution combinations with the numbering of the substitued amio acid resides equivalent to the numbering of Bacillus amyloliquefaciens subtilisin (subtilisin BPN').
  • subtilisin of the invention comprises at least three, even more preferably at least four and most preferably at least five of said mutations (a) to (c).
  • the subtilisin of the invention with at least two modifications (a) to (e) includes:
  • subtilisin according to embodiment (1) which has a mutation (a), preferably the modification E54D, and has at least one (1), preferably at least two (2), more preferably at least three (3) and most preferably at least four (4) - additional mutations selected from the mutations (b) to (e) (particularly preferred is a subtilisin according to (i) above which has at least the additional modifications Q103R and E156A);
  • a subtilisin according embodiment (1) which has a mutation (b), preferably the modification Q103R, and has at least one (1), preferably at least two (2), more preferably at least three (3) and most preferably at least four (4) additional mutations selected from the mutations (a) and (c) to (e) (particularly preferred is a subtilisin defined above, which has modifications Q103R and E156A and at least one further modification (a), (c) or (e), preferably the additional mutation T133K);
  • the improved subtilisin variant comprises a combination of at least any two of the following group of amino acid substitutions: E54D, Q103R, T133K, E156A, Y217H.
  • the subtilisin variants according to embodiments (1) and (2) of the present invention may comprise additional amino acid substitution including substitutions at the following positions: 4, 5, " 6, 7, 9, 14, 15, 17, 18, 19, 20, 24, 25, 31, 38, 43, 45, 49, 50, 51, 54 modified differently as compared to mutation (a), 56, 59, 61, 63, 78, 79, 89, 90, 101, 103 modified differently as compared to mutation (b), 104, 111, 118, 130, 133 modified differently as compared to mutation (c), 136, 138, 145, 149, 150, 156 modified differently as compared to mutation (d), 157, 161, 164, 167, 173, 181, 183, 184, 185, 191, 197, 199, 204, 206, 209, 217 modified differently as compared to mutation (e), 218, 224, 228, 234, 235, 242, 243, 245, 247, 248, 249, 251, 252, 253, 259, 263, 265, 271, 267, 269
  • the additional mutation is selected from the following group of amino acid substitutions:
  • the improved subtilisin is one of the following variants comprising particular combinations of amino acid substitutions (with the numbering of the substituted amino acid resides equivalent to the numbering of subtilisin BPN'):
  • variant 1 Y6N/I31L/S38T/F50I/Q103R
  • variant 2 P14T/Q103R/T130I/Q185H/K265N
  • variant 3 V51I/Q103R/E156A
  • variant 4 Q103R/V138A/A150V/E156A/Y217H/Q271H
  • variant 5 S9P/R45S/Q103R/T130A/E156G/S183N/Y217H
  • variant 6 G61S/S78P/Q103R/E156A/ variant 7: E54D/I79F/Q103R/E156G/Y217H/N243S
  • variant 8 S78P/ L90I/Q103R/E156A
  • variant 9 Q103K/T130A/E156G/L209H
  • variant 10 Q103K/E156A/T242A/N259H
  • variant 11 N25D/Q103K/E156A
  • variant 12 P14T/Q103R
  • variant 30 E54D/Q103R/I111N/N118Y/T130A/E156A/Q185H
  • variant 31 E54D/T130A/V149I/E156A/S183N/D197G/Q206H/N218I/N269I
  • variant 32 E54D/Q103R/T133K/K136N/E156A/N269D
  • variant 33 Y6N/P14T/A15V/I31L/N43S/E54D/Q103R/E156A
  • variant 34 P14T/A15V/E54D/Q103R/E156A/Y167F/Y217H/N218T
  • variant 35 P14T/A15V/I31L/E54D/Q103R/N118Y/E156A/S191G/N243T/Y263C/
  • variant 36 G7S/S9A/Q103R/T133K/E156A/Y217H/T224A/Y263N/A272P
  • variant 37 E54D/Q103R/T133K/K136N/E156A/Y217H
  • variant 38 S9P/Q103R/T133K/E156A/T164S/S183N/Y217H
  • variant 39 E54D/Q103R/T133K/E156A/N184Y/Q206L/Y217H/K265N
  • variant 40 P5L/Y6H/S49G/Q103R/T133K/E156A/Y217H
  • variant 41 E54G/Q103R/I111V/V138A/A150V/E156A/Y217H/L235I
  • variant 42 S89P/Q103R/E156A/Q271H
  • variant 43 I31L/N43S/N56S/Q103R/
  • variants 1 to 50 those derived from subtilisin E as shown in SEQ ID NOs: 10 to 59 are particularly preferred.
  • subtilisin variants that surprisingly show enhanced characteristics compared to the precursor subtilisin.
  • the subtilisin variants have distinguishing properties, such as improved catalytic actitvity as compared to the precursor subtilisins.
  • the subtilisin variants of interest in this invention have a lower Km and a higher catalytic activity in comparision to the precursorsubtilisin.
  • the subtilisin variants of interest in this invention surprisingly show an improved wash perfonnance in laundry detergent. The improvement of wash performance is connected with a better result in proteinaceous stain removal, or otherwise stated less of the subtilisin variant has to be added to obtain the same result as with the precursor subtilisin.
  • these variants show a better stability in presence of typical ingredients of cleaning composition as oxidizing agents.
  • the invention comprises also the use of the subtilisin variants as defined herein before as additiv in a cleaning composition.
  • This cleaning composition may be used as laundry detergent or a dishwasher detergent.
  • Example I Cloning of the subtilisin E gene and extracelluar expression by B. subtilis
  • the aprE gene coding for subtilisin E was amplified by PCR from the genome of Bacillus subtilis strain 168 (DSM #402). Amplification was performed for 20 cycles using a 5: 1 mixture of Taq and Pfu polymerases while B. subtilis cells served as templates.
  • the gene was ligated into the vector pBVl behind the P43 promotor.
  • the vector pBVl was constructed as follows: The pMBl origin from pUC19 (ATCC 37254) was PCR amplified (positions 763 - 1601) and introduced into the PvuII site of pUBHO (ATCC 37015).
  • subtilisin E gene (Seq. ID: 60) from the genome of Bacillus subtilis strain 168 (DSM #402) without the signal sequence as well as any other subtilisin variant was introduced in frame with the signal sequence into the multiple cloning site resulting in the vector pBVP43-Sub (J. Biol. Chem. 1984, 259 (13), 8619-8625; - Biotechnol. Bioeng. 1999, 62 (1), 87-96). Mutagenesis was restricted to the DNA sequence encoding the mature subtilisin (amino acid sequence of subtilisin E in Seq. ID: 2) without affecting the N-terminal signal sequence.
  • the vector construct is schematically shown in Figure 1.
  • subtilis clone transformed with a pBVP43-Sub plasmid encoding the particular variant, and incubation in Erlenmeyer flasks for 24 to 48 h at 30°C with continuous shaking. After separation of the cells by centrifugation, either the supernatant was used directly for enzyme characterization, or the enzyme was further purified by salt precipitation, ion exchange chromatography, dialysis and subsequent lyophilization. Concentration of the enzyme in solution was determined by standard protein quantification methods such as the Bradford test. Purity and integrity of the final enzyme was analyzed by SDS polyacrylamide gel electrophoresis.
  • subtilisin variants with improved characteristics were generated by means of directed evolution essentially following the protocol provided in WO9218645 in combination with screening methods as provided in WO9416313 or WO9934195. According to these methods, the gene coding for subtilisin E was mutagenized by replication using a DNA polymerase with an error rate in the region of the error threshold. Typically, a modified PCR was used for this purpose.
  • Ligation into the vector was done using 300 fmol vector, 1500 f ol insert, 2 ⁇ l of lOx Ligation buffer (500 mM Tris-HCl, pH 7.5; 100 mM MgCI 2 ; 100 mM DTT; 10 mM ATP, 250 ⁇ g/ml BSA), 5 Weiss Units of T4 DNA ligase (MBI Fermentas), ad 20 ⁇ l aqua dest, by incubation for 2 h at room temperature, followed by heat inactivation for 10 min at 65 °C, and ethanol precipitation. The ligation mixture was then transformed into electrocompetent E. coli XLl-Blue. After preparation of the resulting DNA product from E.
  • lOx Ligation buffer 500 mM Tris-HCl, pH 7.5; 100 mM MgCI 2 ; 100 mM DTT; 10 mM ATP, 250 ⁇ g/ml BSA
  • MBI Fermentas T4 DNA ligas
  • subtilisin variants produced by B. subtilis cells in the particular compartments were then examined under conditions relevant to the final application by ultra high throughput screening with confocal fluorescence spectroscopy (see WO9416313 or WO9934195).
  • Genes coding for subtilisin variants with improved characteristics under the screening conditions were subsequently selected and isolated by means of PCR amplification, recloned and re-mutagenized. This cycle of mutagenesis, screening and selection was repeated several times.
  • the genes coding for selected variants were analyzed by sequencing.
  • mutations occurring in different variants selected in a screening round were combined by means of standard restriction and ligation methods or alternatively by means of homologous recombination methods, e.g. as provided in WO0134835.
  • An example of the continuous , improvement of subtilisin characteristics by directed evolution over 4 rounds is shown in Figure 3.
  • Example III Protein degradation performance of improved subtilisin variants in detergent
  • subtilisin variants The improvement of subtilisin variants was analyzed by measuring the rate of hydrolysis of protein substrates.
  • Bovine serum albumin (BSA, obtained from Sigma) as an exemplary globular protein was labeled with the fluorescent dye TIRTC (obtained from Sigma) resulting in a labeling degree of approximately one mol dye per mol protein.
  • TIRTC fluorescent dye obtained from Sigma
  • the degradation of the labelled protein was measured in solution by single-molecule anisotropy, fluorescence correlation spectroscopy and fluorescence intensity measurements using a confocal fluorescence spectroscopy set-up (see WO9416313).
  • FITC-labelled casein casein obtained from Sigma, FITC obtained from Fluka was used as a substrate.
  • Example IV Effect of improved variants on protein solubilization and subsequent degradation from textiles
  • Standard cotton (Nr. 10A, wfk Testgewebe GmbH, Christenfeld 10, D41379 Br ⁇ ggen-Bracht, Germany) was impregnated with 20% hen egg solution containing TIRTC labelled BSA. Then the cotton was cut into pieces, dried, washed three times with laundry detergent containing no protease, dried again and then incubated with laundry detergent containing the particular subtilisin variant, or commercially available subtilisin variant, both at 2.5 mg/l,- or no protease as control.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP02793057A 2001-12-21 2002-12-18 Subtilisin varianten mit verbesserten eigenschaften Withdrawn EP1461409A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02793057A EP1461409A2 (de) 2001-12-21 2002-12-18 Subtilisin varianten mit verbesserten eigenschaften

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01130636 2001-12-21
EP01130636A EP1321513A1 (de) 2001-12-21 2001-12-21 Subtilisin variante mit verbesserten Eigenschaften
EP02793057A EP1461409A2 (de) 2001-12-21 2002-12-18 Subtilisin varianten mit verbesserten eigenschaften
PCT/EP2002/014448 WO2003054127A2 (en) 2001-12-21 2002-12-18 Subtilisin variants with improved characteristics

Publications (1)

Publication Number Publication Date
EP1461409A2 true EP1461409A2 (de) 2004-09-29

Family

ID=8179648

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01130636A Withdrawn EP1321513A1 (de) 2001-12-21 2001-12-21 Subtilisin variante mit verbesserten Eigenschaften
EP02793057A Withdrawn EP1461409A2 (de) 2001-12-21 2002-12-18 Subtilisin varianten mit verbesserten eigenschaften

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01130636A Withdrawn EP1321513A1 (de) 2001-12-21 2001-12-21 Subtilisin variante mit verbesserten Eigenschaften

Country Status (3)

Country Link
EP (2) EP1321513A1 (de)
AU (1) AU2002358746A1 (de)
WO (1) WO2003054127A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526399T1 (de) 2003-06-18 2011-10-15 Bayer Pharma AG Neue biologische einheiten und deren verwendung
DE102007051092A1 (de) * 2007-10-24 2009-04-30 Henkel Ag & Co. Kgaa Subtilisin aus Becillus pumilus und Wasch- und Reinigungsmittel enthaltend dieses neue Subtilisin
EP2607468A1 (de) * 2011-12-20 2013-06-26 Henkel AG & Co. KGaA Reinigungsmittelzusammensetzungen mit Subtilasevarianten
EP3044313B1 (de) * 2013-09-12 2019-11-06 Danisco US Inc. Zusammensetzungen und verfahren mit protease varianten der lg12-klade
MX2017006695A (es) 2014-12-04 2017-08-21 Novozymes As Variantes de subtilasa y polinucleotidos que las codifican.
DE102016204814A1 (de) 2016-03-23 2017-09-28 Henkel Ag & Co. Kgaa Verbesserte Reinigungsleistung an Protein sensitiven Anschmutzungen
EP3768835A1 (de) * 2018-03-23 2021-01-27 Novozymes A/S Subtilasevarianten und zusammensetzungen damit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116741A (en) * 1988-04-12 1992-05-26 Genex Corporation Biosynthetic uses of thermostable proteases
DK316989D0 (da) * 1989-06-26 1989-06-26 Novo Nordisk As Enzymer
GB9027836D0 (en) * 1990-12-21 1991-02-13 Unilever Plc Enzymes and enzymatic detergent compositions
US5567601A (en) * 1993-06-01 1996-10-22 University Of Maryland Subtilisin mutants lacking a primary calcium binding site
HUT74222A (en) * 1993-09-15 1996-11-28 Procter & Gamble Subtilisin bpn' variants with decreased adsorption and increased hydrolysis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03054127A3 *

Also Published As

Publication number Publication date
WO2003054127A2 (en) 2003-07-03
WO2003054127A3 (en) 2004-03-04
AU2002358746A1 (en) 2003-07-09
EP1321513A1 (de) 2003-06-25

Similar Documents

Publication Publication Date Title
US6300116B1 (en) Modified protease having improved autoproteolytic stability
KR100258460B1 (ko) 안정화 효소 및 세제 조성물
KR100660746B1 (ko) 활성부위 루프 영역에 추가적 아미노산 잔기를 가지는서브그룹 ｉ-ｓ１과 ｉ-ｓ２의 서브틸라제 효소
RU2136756C1 (ru) Модифицированный субтилизин, днк, кодирующая модифицированный субтилизин, вектор экспрессии, кодирующий днк, и штамм культуры клетки хозяина
CN115427563A (zh) 稳定性增强的蛋白酶变体vi
CN115516088A (zh) 性能增强的蛋白酶变体vii
KR100660818B1 (ko) 활성부위 루프 영역에 추가적 아미노산 잔기를 가지는서브그룹 ｉ-ｓ１과 ｉ-ｓ２의 서브틸라제 효소
AU2014336474B2 (en) Protease variants with increased stability
KR20130009770A (ko) 성능-증강된 프로테아제 변이체
KR102309234B1 (ko) 세제에서의 개선된 효소 안정성을 갖는 프로테아제
KR102309233B1 (ko) 단백질 민감성 오염에 대한 개선된 세정 성능
CA2355619C (en) Subtilase enzymes of the i-s1 and i-s2 sub-groups having an additional amino acid residue in an active site loop region
EP1461409A2 (de) Subtilisin varianten mit verbesserten eigenschaften
EP1183343A1 (de) Subtilase-enzyme der i-s1 und i-s2 untergruppen mit wenigstens einem zusätzlichen aminosäurerest zwischen positionen 125 und 126
US20030157645A1 (en) Subtilisin variants with improved characteristics
KR100767710B1 (ko) 위치 97 및 98 사이에 적어도 하나의 추가의 아미노산잔기를 가지는 ｉ-ｓ1 및 ｉ-ｓ2 아군의 서브틸라제 효소
CA2355947C (en) Subtilase enzymes of the i-s1 and i-s2 sub-groups having an additional amino acid residue in an active site loop region
KR100660806B1 (ko) 활성부위 루프 영역에 추가적 아미노산 잔기를 가지는서브그룹 ｉ-ｓ１과 ｉ-ｓ２의 서브틸라제 효소
KR100660799B1 (ko) 활성부위 루프 영역에 추가적 아미노산 잔기를 가지는서브그룹 ｉ-ｓ１과 ｉ-ｓ２의 서브틸라제 효소
KR100649912B1 (ko) 활성부위 루프 영역에 추가적 아미노산 잔기를 가지는서브그룹 ｉ-ｓ1과 ｉ-ｓ2의 서브틸라제 효소
KR100660742B1 (ko) 활성부위 루프 영역에 추가적 아미노산 잔기를 가지는서브그룹 ｉ-ｓ１과 ｉ-ｓ２의 서브틸라제 효소
JP4050654B6 (ja) 安定化酵素及び洗剤
EP1183339A1 (de) Subtilase enzyme der i-s1 und i-s2 untergruppen mit mindestens einer zusätzlichen aminosäure zwischen position 129 und 130
AU4392600A (en) Subtilase enzymes of the I-S1 and I-S2 sub-groups having at least one additional amino acid residue between positions 97 and 98

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040630

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/54 20060101ALI20061128BHEP

Ipc: C11D 7/42 20060101ALI20061128BHEP

Ipc: C11D 3/386 20060101ALI20061128BHEP

Ipc: C12N 9/56 20060101AFI20061128BHEP

17Q First examination report despatched

Effective date: 20070126

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080328